Retinoids and human breast cancer: in vivo effects of an antagonist for RAR-alpha.
Salvatore Toma, Laura Emionite, Angelo Scaramuccia, Giambattista Ravera, Linda Scarabelli
Index: Cancer Lett. 219(1) , 27-31, (2005)
Full Text: HTML
Abstract
The aim of the present study was to evaluate the in vivo effects of the RAR-alpha selective antagonist Ro 41-5253 on a xenograft animal model for breast cancer. Our observations indicate a lack of toxic side effects of the drug, even when used at high dosages. It is interesting to note that using Ro 41-5253 at dosages of 10, 30 and 100 mg/kg/die resulted in a slight, but significant inhibition of cell growth. The data obtained in this study represents the basis for a further evaluation of Ro 41-5253 anti-neoplastic activity on transgenic breast cancer animal models.
Related Compounds
Related Articles:
Effect of all-trans-retinoic acid on enterovirus 71 infection in vitro.
2014-05-01
[Br. J. Nutr. 111(9) , 1586-93, (2014)]
Retinoic acid inhibits in vivo interleukin-2 gene expression and T-cell activation in mice.
2009-04-01
[Immunology 126(4) , 514-22, (2009)]
2002-06-01
[Exp. Lung Res. 28(4) , 315-32, (2002)]
Retinoic acid signaling is necessary for the development of the organ of Corti.
1999-09-01
[Dev. Biol. 213(1) , 180-93, (1999)]
1998-03-15
[Exp. Cell Res. 239(2) , 320-5, (1998)]